Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load

被引：0
作者：
Baijun Li
Zhaozhe Liu
Xing Liu
Dongchun Liu
Mingyu Duan
Ye Gu
Qiong Liu
Qiang Ma
Yushi Wei
Yan Wang
机构：
[1] The Sixth People’s Hospital of Shenyang,Cadre’s Ward
[2] General Hospital of Northern Theater Command,Oncology Department
[3] The Sixth People’s Hospital of Shenyang,Science and Education Department
[4] Shenyang Pharmaceutical University,School of Traditional Chinese Materia Medica
[5] Shenyang Beichuang Laboratory Co. Ltd,Clinical Chemistry Laboratory
[6] The Sixth People’s Hospital of Shenyang,Gastroenterology Departmentepartment
[7] Liaoning University of Traditional Chinese Medicine,undefined
来源：
Hepatology International | 2021年 / 15卷
关键词：
Tenofovir disoproxil fumarate; Tenofovir alafenamide fumarate; HBV vertical transmission; Pregnant women; Perinatal period; Drug safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1103 / 1108
页数：5
相关论文
共 50 条
  • [21] Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient
    Mothobi, Nomvuyo Z.
    Masters, Jeffrey
    Marriott, Deborah J.
    THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2018, 5 (05) : 91 - 95
  • [22] Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate
    Huhn, Gregory D.
    Shamblaw, David J.
    Baril, Jean-Guy
    Hsue, Priscilla Y.
    Mills, Brittany L.
    Thai Nguyen-Cleary
    McCallister, Scott
    Das, Moupali
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (01):
  • [23] Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial
    Hamzah, L.
    Williams, D.
    Bailey, A. C.
    Jones, R.
    Ibrahim, F.
    Musso, C. G.
    Burling, K.
    Barbini, B.
    Campbell, L.
    Post, F. A.
    Hamzah, Lisa
    Campbell, Lucy
    Adegbaju, Oluwayomi
    Engler, Birgit
    Bhagwandin, Priya
    Santana-Suarez, Beatriz
    Post, Frank
    Johnson, Margaret
    Hemat, Nargis
    Ngwu, Nnenna
    Nightingale, Alice
    Edwards, Jonathan
    Fernandez, Thomas
    Williams, Deborah
    Richardson, Celia
    Campbell, Marion
    Trevitt, Vittorio
    Jones, Rachael
    Fedele, Serge
    Bisdomini, Elisa
    Montauri, Laura
    Thunder, Orla
    Morrish, Thomas
    Soler-Carracedo, Alfredo
    Martinez-Berlanga, Andrea
    Bailey, Angela
    Alagaratnam, Jasmini
    Legg, Ken
    Petersen, Claire
    Clift, Paul
    Cromarty, Ben
    HIV MEDICINE, 2020, 21 (03) : 198 - 203
  • [24] Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials
    Gupta, Samir K.
    Post, Frank A.
    Arribas, Jose R.
    Eron, Joseph J., Jr.
    Wohl, David A.
    Clarke, Amanda E.
    Sax, Paul E.
    Stellbrink, Hans-Juergen
    Esser, Stefan
    Pozniak, Anton L.
    Podzamczer, Daniel
    Waters, Laura
    Orkin, Chloe
    Rockstroh, Juergen K.
    Mudrikova, Tatiana
    Negredo, Eugenia
    Elion, Richard A.
    Guo, Susan
    Zhong, Lijie
    Carter, Christoph
    Martin, Hal
    Brainard, Diana
    SenGupta, Devi
    Das, Moupali
    AIDS, 2019, 33 (09) : 1455 - 1465
  • [25] Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
    He, Jingjing
    Guo, Yifei
    Zhang, Yao
    Han, Jiajia
    Chen, Jingwen
    Jia, Yidi
    Ma, Zhenxuan
    Wu, Jingwen
    Zhang, Shenyan
    Li, Fahong
    Mao, Richeng
    Zhang, Jiming
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 3929 - 3941
  • [26] The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
    Wang, Huilian
    Lu, Xi
    Yang, Xudong
    Xu, Nan
    MEDICINE, 2016, 95 (41)
  • [27] Improvement of hepatic fibrosis after tenofovir disoproxil fumarate switching to tenofovir alafenamide for three years
    Huynh, Tung
    Bui, Delana MyAn
    Zhou, Tina Xiwen
    Hu, Ke-Qin
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (07) : 1009 - 1017
  • [28] Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B
    Liu, Rui
    Qiao, Jin
    Zhang, Lin
    Dou, Zhihua
    MEDICINE, 2024, 103 (20) : E37953
  • [29] High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate
    Margot, Nicolas A.
    Liu, Yang
    Miller, Michael D.
    Callebaut, Christian
    ANTIVIRAL RESEARCH, 2016, 132 : 50 - 58
  • [30] Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function
    Quesada-Lopez, T.
    Cereijo, R.
    Blasco-Roset, A.
    Mestres-Arenas, A.
    Prieto, P.
    Domingo, J. C.
    Villarroya, F.
    Domingo, P.
    Giralt, M.
    BIOCHEMICAL PHARMACOLOGY, 2024, 220
12345